Details for Patent: 7,645,801

Which drugs does patent 7,645,801 protect, and when does it expire?

Patent 7,645,801 protects SFROWASA and is included in one NDA.

This patent has seven patent family members in seven countries.

Summary for Patent: 7,645,801

Scope and claims summary:

Title:	Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
Abstract:	The present invention comprises packaged enemas for the treatment of Inflammatory Bowel Disease (IBD), having substantially pure 5-ASA as the active ingredient, with a liquid carrier medium having a material avoidance of bowel irritant substances, such as anti-oxidants for the 5-ASA active ingredient, including such sulfites as potassium metabisulfite, for example, and contained within a sealed and substantially oxygen-free barrier package, which may preferably be formed of a foil/polymer laminate, and which package contains or otherwise includes an oxygen scavenger, such as a an oxygen scavenging sachet.
Inventor(s):	Venkataraman; Bala (Alpharetta, GA), Brown; Lindsey (Atlanta, GA), Patel; Daxa (Marietta, GA)
Assignee:	Alaven Pharmaceutical LLC (Marietta, GA)
Application Number:	11/749,732
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 7,645,801

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mylan Speciality Lp	SFROWASA	mesalamine	ENEMA;RECTAL	019618-002	Jun 20, 2008	AB	RX	Yes	No	7,645,801		Y	Y

International Family Members for US Patent 7,645,801

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2008211124
Canada	2677095
Denmark	2107870
European Patent Office	2107870